ArticleNeuroImage. Clinical2017
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.
Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 63 citations in OpenAlex.
- Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.Journal of neurology · 2026Observational
- Frailty Exacerbates Disability in Progressive Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis: An Association With Disease Progression.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- An MRI assessment of mechanisms underlying lesion growth and shrinkage in multiple sclerosis.Annals of clinical and translational neurology · 2025Article
- Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.Journal of neurology · 2024Observational
- Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.Journal of neurology · 2024Article
- Cognitive function in severe progressive multiple sclerosis.Brain communications · 2024Article
- Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.Journal of neurology · 2023Article
- Learning from pseudo-labels: deep networks improve consistency in longitudinal brain volume estimation.Frontiers in neuroscience · 2023Article
- Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study.Brain communications · 2023Article
- Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy.Annals of clinical and translational neurology · 2022Article
- Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2022Article
- Quantitative comparison of subcortical and ventricular volumetry derived from MPRAGE and MP2RAGE images using different brain morphometry software.Magma (New York, N.Y.) · 2021Article
- Automated Assessment of the Substantia Nigra Pars Compacta in Parkinson's Disease: A Diffusion Tensor Imaging Study.Journal of personalized medicine · 2021Article
- Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.NeuroImage. Clinical · 2021Article
- DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.NeuroImage. Clinical · 2021Article
- Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2020Article
- MRI biomarkers of disease progression in multiple sclerosis: old dog, new tricks?Quantitative imaging in medicine and surgery · 2020Article
- LesionQuant for Assessment of MRI in Multiple Sclerosis-A Promising Supplement to the Visual Scan Inspection.Frontiers in neurology · 2020Article
- Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundThere is a need for a brain volume measure applicable to the clinical routine scans. Nearly every multiple sclerosis (MS) protocol includes low-resolution 2D T2-FLAIR imaging.
objectivesTo develop and validate cross-sectional and longitudinal brain atrophy measures on clinical-quality T2-FLAIR images in MS patients.
methodsA real-world dataset from 109 MS patients from 62 MRI scanners was used to develop a lateral ventricular volume (LVV) algorithm with a longitudinal Jacobian-based extension, called NeuroSTREAM. Gold-standard LVV was calculated on high-resolution T1 1 mm, while NeuroSTREAM LVV was obtained on low-resolution T2-FLAIR 3 mm thick images. Scan-rescan reliability was assessed in 5 subjects. The variability of LVV measurement at different field strengths was tested in 76 healthy controls and 125 MS patients who obtained both 1.5T and 3T scans in 72 hours. Clinical validation of algorithm was performed in 176 MS patients who obtained serial yearly MRI 1.5T scans for 10 years.
resultsCorrelation between gold-standard high-resolution T1 LVV and low-resolution T2-FLAIR LVV was r = 0.99, p < 0.001 and the scan-rescan coefficient of variation was 0.84%. Correlation between low-resolution T2-FLAIR LVV on 1.5T and 3T was r = 0.99, p < 0.001 and the scan-rescan coefficient of variation was 2.69% cross-sectionally and 2.08% via Jacobian integration. NeuroSTREAM showed comparable effect size (d = 0.39-0.71) in separating MS patients with and without confirmed disability progression, compared to SIENA and VIENA.
conclusionsBrain atrophy measurement on clinical quality T2-FLAIR scans is feasible, accurate, reliable, and relates to clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.